Particle.news
Regulatory Affairs Pharmaceuticals Clinical Trials Patient Care Public Health Neurology FDA Stock Market Medical Research Clinical Research
The panel's unanimous vote coincides with new FDA policies restricting booster eligibility for healthy individuals under 65 without additional trials.
